Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Grace Therapeutics (GRCE)
NASDAQ:GRCE
RESEARCH TOOLSreports
Holding GRCE?
Track your performance easily
GRCE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.98 - $4.97
Previous Close$3.82
Volume30.58K
Average Volume (3M)51.32K
Market Cap
$41.17M
Enterprise Value$21.76M
Total Cash (Recent Filing)$19.41M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Feb 17, 2025EPS Estimate
-$0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares Outstanding10,140,000
10 Day Avg. Volume227,377
30 Day Avg. Volume51,321
Standard Deviation0.29
R-Squared0.08
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.65
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.59
Forecast
1Y Price Target
$12.00Price Target Upside214.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Grace Therapeutics News
PremiumCompany Announcements
Grace Therapeutics Reports Steady Progress and Financials
Ownership Overview
―
Insiders
9.46% Other Institutional Investors
88.32% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
GRCE FAQ
What was Grace Therapeutics’s price range in the past 12 months?
Grace Therapeutics lowest stock price was $1.98 and its highest was $4.96 in the past 12 months.
What is Grace Therapeutics’s market cap?
Currently, no data Available
When is Grace Therapeutics’s upcoming earnings report date?
Grace Therapeutics’s upcoming earnings report date is Feb 17, 2025 which is in 57 days.
How were Grace Therapeutics’s earnings last quarter?
Grace Therapeutics released its earnings results on Nov 13, 2024. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.37 by $0.07.
Is Grace Therapeutics overvalued?
According to Wall Street analysts Grace Therapeutics’s price is currently Undervalued.
Does Grace Therapeutics pay dividends?
Grace Therapeutics does not currently pay dividends.
What is Grace Therapeutics’s EPS estimate?
Grace Therapeutics’s EPS estimate is -$0.32.
How many shares outstanding does Grace Therapeutics have?
Grace Therapeutics has 10,139,861 shares outstanding.
What happened to Grace Therapeutics’s price movement after its last earnings report?
Grace Therapeutics reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.37. Following the earnings report the stock price went down -4.389%.
Which hedge fund is a major shareholder of Grace Therapeutics?
Currently, no hedge funds are holding shares in GRCE
---
Grace Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (214.14% Upside)
$12.00 (214.14% Upside)
Blogger Sentiment
Bullish
GRCE Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.53%
12-Months-Change
Fundamentals
Return on Equity
-18.89%
Trailing 12-Months
Asset Growth
-16.44%
Trailing 12-Months
Company Description
Grace Therapeutics
Acasti Pharma, Inc. engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland on February 1, 2002 and is headquartered in Laval, Canada.
---
GRCE Earnings Call
Q3 2023
0:00 / 0:00
---
GRCE Stock 12 Month Forecast
Average Price Target
$12.00
▲(214.14% Upside)
Technical Analysis
Avenue Therapeutics
―
Cyclacel Pharmaceuticals
―
ESSA Pharma
―
SELLAS Life Sciences Group
―
Best Analysts Covering GRCE
1 Year
1 Year Success Rate
5/5 ratings generated profit
1 Year Average Return
+45.78%
assigned a buy rating 27 days ago
Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +45.78% per trade.
---